◀ Back to IL4

IL4 — PGP

Text-mined interactions from Literome

Gollapudi et al., Genes Immun 2000 : These data show that P-gp is not required for secretion of IL-2, IFN-gamma, IL-4 , and IL-10 secretion in mice and IL-2 secretion in humans
Li et al., Zhonghua Zhong Liu Za Zhi 2001 (Hepatoblastoma...) : The level of P-gp expression in ATRA treated cells was increased from 54.2 % +/- 8.6 % up to 98.5 % +/- 1.4 % ( P < 0.01 ), but IL-4 markedly inhibited expression of P-gp down to 25.4 % +/- 7.3 % ( P < 0.01 )
Bonhomme-Faivre et al., Anticancer Drugs 2002 : Based on the premise that Taxol pharmacokinetic parameters could be modified as a result of diminished P-gp expression induced by recombinant interleukin ( rIL ) -2 and that this might elicit an interaction between the two drugs, we evaluated the pharmacokinetics of a novel strategy combining i.p. immunotherapy with rIL-2 and a cytotoxic agent, Taxol
Pawlik et al., J Pharm Pharmacol 2005 : P-gp inhibitors suppressed the release of IL-2, IL-4 , IFN-gamma and TNF-alpha from PHA stimulated MNC, whereas release of IL-6 and IL-10 remained unaffected
Izawa et al., Biochem Biophys Res Commun 2010 : Moreover, P-gp blockade, compared to controls, attenuated intragraft expression of CD3 and CD80, but not CD86, and inhibited IFN-gamma and IL-4 production ( P < 0.05 ) ... In the setting of systemic CD86 inhibition, P-gp blockade suppressed IFN-gamma and IL-4 production significantly further ( to 98 % and 89 % inhibition, respectively ) compared to either P-gp or anti-CD86 blockade alone, and markedly prolonged allograft survival compared to anti-CD86 blockade alone ( 40.5+/-4.6 versus 22.5+/-2.6 days, respectively, P < 0.01 )
Azuma et al., Eur J Haematol 1997 (Leukemia, Experimental) : Monoclonal antibody against interleukin-4 (IL-4) abrogated the IL-4 induced suppression of P-gp